Orforglipron

1. 01Gut

   A tablet is absorbed through the gut

   Peptide drugs are usually broken down by stomach acid and enzymes, so they are injected. Orforglipron is a small, sturdy molecule that survives digestion and passes into the blood. About three quarters of it gets in.

   For experts

   Orforglipron is a non-peptide small molecule, so it is not degraded by gastrointestinal proteases as peptide agonists are. Peak plasma concentration occurs 4 to 8 hours after an oral dose. Geometric mean absolute bioavailability was 77% in the label and 79.1% in a dedicated phase 1 study. Food had no clinically relevant effect on exposure.[src][src]

2. 02Bloodstream

   Stays in the blood for more than a day

   Nearly all of the drug sticks to proteins in the blood, and the body clears it slowly. Its half-life is about one to two days, so a single tablet a day keeps a steady amount in the body.

   For experts

   Plasma protein binding exceeds 99%, steady-state volume of distribution is about 285 L and systemic clearance is 7.15 L/h. Elimination half-life is about 29 to 49 hours, and steady state is reached after about one week of once-daily administration.[src]

3. 03Pancreas

   Switches on GLP-1 receptors on pancreas cells

   Orforglipron fits into GLP-1 receptors, a kind of lock on the surface of cells. In the pancreas this helps the body release insulin when blood sugar is high. In a diabetes trial it lowered average blood sugar.

   For experts

   It binds and activates the human GLP-1 receptor with high affinity (Ki about 1 nM) and is selective over other class B GPCRs. It is a partial agonist biased toward G-protein signalling over beta-arrestin recruitment, and low receptor occupancy was sufficient for a full glucose response in humanized-receptor mice (animal data). In humans, a phase 2 analysis showed improved beta-cell function markers (HOMA-B) in type 2 diabetes, and ACHIEVE-1 showed HbA1c reductions of 1.24 to 1.48 percentage points over 40 weeks against 0.41 with placebo.[src][src][src][src][src]

4. 04Brain

   Turns down appetite signals in the brain

   GLP-1 receptors also sit in parts of the brain that control hunger. People taking it eat less, probably because they feel less hungry. Only animal studies show that the drug reaches these brain areas; in people, only the drop in eating has been measured.

   For experts

   GLP-1 receptors are present in appetite-regulating brain regions. The label states that in animal studies orforglipron distributed to and activated neurons in these regions; in a rat model engineered to carry a sensitized GLP-1R, target engagement in the brain was consistent with peptide-based agonists (animal-only data). In humans the label reports decreased food intake, likely mediated by decreased appetite. Direct brain-receptor engagement has not been demonstrated in humans.[src][src]

5. 05Stomach

   Slows how fast the stomach empties

   Food leaves the stomach more slowly, which can make people feel full for longer. This effect is biggest after the first dose and fades over time. It also helps explain some side effects, such as nausea.

   For experts

   The label reports delayed gastric emptying that is largest after the first dose and diminishes over time, with the potential to affect absorption of co-administered oral drugs and a warning about pulmonary aspiration during anaesthesia or deep sedation. Gastrointestinal adverse reactions were most frequent during dose escalation and decreased over time.[src]

6. 06Fat tissue

   Body weight goes down, mostly from fat

   With less appetite, people eat less and lose weight. In a large 72-week trial of adults with obesity but not diabetes, the highest dose group lost 11.2% of body weight on average, compared with 2.1% on placebo. More of the lost weight was fat than muscle and other lean tissue.

   For experts

   In ATTAIN-1 (n=3,127), mean body-weight change at week 72 ranged from -7.5% to -11.2% across three doses versus -2.1% with placebo (P<0.001). In the top dose group, 54.6% lost at least 10% of body weight versus 12.9% on placebo. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol also improved. The label states weight loss came with greater fat-mass loss than lean-mass loss.[src][src]

7. 07Liver

   The liver breaks it down and it leaves in stool

   The liver changes the drug into other substances, mostly using an enzyme called CYP3A4. Nearly all of it leaves the body in stool, and very little in urine.

   For experts

   Orforglipron is metabolised primarily by hepatic CYP3A4 to oxidative metabolites that are excreted into the intestinal lumen, followed by gut-microbial metabolism of the oxadiazolone ring. About 87% of a radiolabelled dose was recovered in faeces and under 1% in urine. Exposure rose 1.7-fold and 4.6-fold in moderate and severe hepatic impairment, and strong CYP3A4 inhibitors or inducers change exposure.[src][src]

Around the world

Is Orforglipron legal where you live?

Related molecules